Editor's Note: This column tracks the latest Wall Street ratings and price targets daily to uncover potential investment opportunities.

📡 Today's Trend Signal

Market context. In the previous session (Aug 24), U.S. equities were mixed — Dow Jones Industrial Average(DJI.US) +0.26% (53,417.16), S&P 500 index(SPX.US) -0.28% (7,652.86), NASDAQ(IXIC.US) -0.76% (25,980.19, a 7th straight daily decline). A semiconductor sell-off dominated: the PHLX Semiconductor(SOX.US) fell 2.7%, storage names led losses (Seagate Technology Holdings PLC(STX.US) -6%, Sandisk Corporation(SNDK.US) -6%, Western Digital Corporation(WDC.US) -5%, SK hynix Inc. Sponsored ADR(SKHY.US) -4.9%), and NVIDIA Corporation(NVDA.US) dropped 2.91% for a 7-session losing streak — its longest since 2022 — as markets digested reports of planned Nvidia price hikes on select AI server configurations. Tech (-1.59%) and energy (-0.76%) lagged while consumer staples (+1.76%) and financials (+1.24%) led. On the news front, Treasury Secretary Bessent announced a new round of Iran sanctions, and President Trump threatened 50% tariffs on Canadian cars, parts, and steel (effective Jan 1, 2027), pressuring auto stocks (GM, Ford). Key catalysts this week: Nvidia Q2 FY27 earnings (Aug 26 AMC) and Fed Chair Warsh's Jackson Hole address.

Four key takeaways from today's ratings actions:

Financials see a wave of upgrades today. The financial sector saw 12 upgrades today (16% of total upgrades). Examples: Alkami Technology Inc(ALKT.US) was raised by J.P. Morgan from $19 to $24; Lincoln National Corp(LNC.US) was raised by Morgan Stanley from $40 to $50; MetLife, Inc.(MET.US) was raised by Morgan Stanley from $103 to $111.

Industrials: One stock, two opposing views. Deere & Company(DE.US) saw both an upgrade and a downgrade today: Barclays, DA Davidson raised its target price, while Truist Securities lowered it. This simultaneous clash between bulls and bears indicates that while the sector is gaining attention, institutions are divided on its short-term valuation.

Industrials are under pressure today. The sector saw 10 downgrades (American Airlines Group Inc.(AAL.US), Alaska Air Group, Inc.(ALK.US), Delta Air Lines, Inc.(DAL.US), etc.), contrasting with the main trend and showing that capital is rotating between sectors rather than going all-in on the long side.

Institutional new coverage is active. Today, 43 new initiations landed across multiple sub-sectors; fresh coverage often signals sell-side re-rating and is worth tracking for follow-on actions.

In short: Financials take center stage today, with Industrials seeing divergence, Industrials face pressure. With 77 upgrades vs 29 downgrades, overall sentiment is warm.

📌 Today's Key Ratings Focus: Truist Securities upgrades CoreWeave(CRWV.US) to $165 (Buy) | William Blair upgrades Analog Devices, Inc.(ADI.US) to $675 (Outperform) | Roth Capital upgrades Semtech Corporation(SMTC.US) to $190 (Buy) | Goldman Sachs initiates Aeva Technologies, Inc. (AEVA.US) at $20 (Neutral) | HC Wainwright & Co. downgrades Fury Gold Mines Limited(FURY.US) to $1.9 (Buy)

Rating Spotlight: Inhibrx Biosciences, Inc.(INBX.US)

HC Wainwright initiates Inhibrx Biosciences, Inc.(INBX.US) at Buy with a $245 target — implying ~+133% upside at the $104.94 price; whether the twin-pipeline catalysts (ozekibart BLA review, INBRX-106 Phase 2 PFS) can validate it is the core question.

Inhibrx Biosciences, Inc.(INBX.US) drew an initiation from HC Wainwright today (Buy, $245 target), implying ~133% upside at $104.94. The re-rating thesis rests on ozekibart (a tetravalent DR5 agonist with an FDA-accepted chondrosarcoma BLA) and INBRX-106 (a hexavalent OX40 agonist with a HexAgon Phase 2 readout imminent) — the crux of market attention.

The fundamentals come from Q2 2026 results disclosed Aug 13: no product revenue, R&D of $23.9M and G&A of $8.3M; cash and equivalents of $133.3M at Jun 30, then a July second amendment to the Oxford Finance loan agreement (up to $325M in new capacity, $100M funded) lifted cash to $219.5M by Aug 6. Pipeline: (1) ozekibart (INBRX-109, tetravalent DR5 agonist) — its chondrosarcoma BLA was accepted by the FDA in June with a PDUFA date of Apr 14, 2027; in 4th-line colorectal cancer, Phase 1/2 data showed a 20% ORR (vs 1-6% historical SOC), 5.5-month median PFS and an 87% DCR, with an FDA meeting planned for Q4 2026 on a 1L registrational trial and accelerated paths; (2) INBRX-106 (hexavalent OX40 agonist) — the HexAgon Phase 2 in HNSCC with pembrolizumab showed a confirmed 44% interim ORR vs 21.4% in the control arm; management guides PFS data in Q3 2026, Phase 3 initiation in Q3, and a perioperative NSCLC study later this quarter.

Today's sample shows only HC Wainwright initiating Inhibrx Biosciences, Inc.(INBX.US) (Buy, $245). The $245 target implies ~+133% upside from the Aug 24 close of $104.94, underwriting optimistic assumptions on ozekibart approval/launch and an INBRX-106 readout. A single-house initiation with a triple-digit implied upside should be discounted; more coverage or data readouts are needed to validate.

At $104.94, Inhibrx Biosciences, Inc.(INBX.US) sits ~+332% above its 52-week low of $24.27 but ~32% below the $155.29 high — the stock has already repriced sharply over the past year and now trades in the upper range, yet sell-side is still pressing for more upside. This is not a sector story: as a clinical-stage biotech, the tape is driven by its own pipeline events (BLA filing, readouts) and financing structure. Skeptics anchor on three things — the pre-revenue profile, unresolved hepatic safety and commercial pricing for ozekibart, and the long wait until the PFS readout and the 2027 PDUFA.

Key questions for subsequent validation:

(1)Can the ozekibart chondrosarcoma BLA (PDUFA Apr 14, 2027) clear review and launch at rare-disease pricing, rather than replaying the slow-ramp, small-market pattern?
(2)Can the INBRX-106 HexAgon Phase 2 PFS data (guided Q3 2026) sustain the 44% ORR and support the Phase 3 start in Q3?
(3)Will the $219.5M cash plus the Oxford facility (up to $325M) last until ozekibart approval, and will trial expansion force equity financing dilution?
(4)The +133% implied upside comes from one initiation — is this the start of a trend re-rating, or a fleeting event-driven overvaluation?

If INBRX-106 PFS reads out positively and ozekibart's approval path stays on track, shares could gravitate toward the $245 target. If data disappoints or the FDA review hits a snag, the bear case revisits the 52-week mid-range or lower. Near-term windows: the Q3 2026 PFS readout, the Q4 FDA CRC meeting, and the Apr 14, 2027 PDUFA.

Overall Assessment:

Summary: Inhibrx Biosciences, Inc.(INBX.US)'s big upside is driven by a single-house initiation. The +133% target price reflects an individual institution's optimistic assumptions rather than market consensus; the key validation for small-cap biotech still depends on upcoming clinical data and regulatory milestones.

📋 Rating Board | Top 10 Upside Potential

Top 10 Upside Potential (Ratings data as of Aug 25)

🔎 Key Observation: Within the Top 10, Fury Gold Mines Limited(FURY.US) / Sequans Communications SA Sponsored ADR(SQNS.US)  saw "target price downgrades"—their stock prices plummeted, but analysts' new targets remain far above current prices, so the "upside" was created by the crash. Such "big upside" reflects survivorship bias; fundamentals should determine whether these are oversold gems or value traps (see Contrarian Radar for details).

Today's Rating Actions: Upgrades 77 | Initiations 43 | Downgrades 29 (Data from public rating sources).

🔬 Recent Institutional Insights

Below is a curated roundup of recent Wall Street views on trending US equities. Provided for informational purposes only.

Analog Devices, Inc.(ADI.US)

Analog Devices drew the day's most dramatic target hike — William Blair lifted it from $450 to $675 (+50%), extending the sell-side repricing of analog/mixed-signal chips on AI power, autos, and industrial demand recovery. The $675 target implies ~+82% upside from the Aug 24 close of $371.17, well above Street consensus, reflecting a single house's bet on cyclical upside; meanwhile, the semiconductor sector weakened on Nvidia price-hike reports and pre-earnings caution — an optimism-vs-tape contrast.

CoreWeave(CRWV.US)

CoreWeave drew a Truist Securities Buy reiteration with the target raised from $155 to $165 — a demand-side confirmation for AI compute supply ahead of Nvidia's print (Aug 26 AMC). The company rents GPU capacity to hyperscalers and AI labs; investors focus on contract visibility and cash-flow conversion. At ~+91% upside from the Aug 24 close of $86.25, the $165 target is growth-priced, with volatility tied to the GPU supply chain and customer concentration.

Jersey Mike's Subs, Inc. Class A(JMKE.US)

Jersey Mike's drew 13 same-day initiations after its listing, with targets clustered at $25-$31 — Bernstein $26, JPMorgan $26, TD $26, Wells Fargo $25, Truist $30 (top), Mizuho $31, RJ/Jefferies/Piper $29, UBS/RBC $28, William Blair $27, Stifel $27 — mostly Buy/Outperform with a few Equal-weight. Thirteen houses covering on day one is rare for a recent IPO; the Street backs its same-store growth and store-expansion model, though the target spread hints at disagreement over valuation digestion.

🎯 Contrarian Radar

Signal 1: Fury Gold Mines Limited(FURY.US) — "Downgraded but retaining massive implied upside" in penny stocks

Fury Gold Mines Limited(FURY.US) was downgraded by HC Wainwright & Co. to $2. With the current price at $0.66, the potential upside is 186.19%. This "artificial upside" emerges when a stock crashes but analysts hold firm on their price targets. It represents a "Market Capitulation vs. Analyst Price Floors" signal, not a consensus bullish view.

Signal 2: Deere & Company(DE.US) — Bulls and Bears Clash, Deere divided

Deere & Company(DE.US) saw upgrades from Barclays, DA Davidson, and others today, alongside downgrades from Truist Securities, with some institutions assigning "Equal-weight." Simultaneous upgrades and downgrades act as a signal in themselves: Deere's long-term consensus is currently detached from its short-term price action.

Signal 3: Initiation Clusters = Fresh Bullish Bets

Today, 43 stocks received initial coverage from brokerages (Aeva Technologies, Inc. (AEVA.US), Alvotech(ALVO.US), Brinker International, Inc.(EAT.US), EverBank Financial Corp.(EVER.US), Fortune Brands Innovations(FBIN.US), Funko, Inc. Class A(FNKO.US), Frontdoor, Inc.(FTDR.US), etc.). This signifies a "wave of new coverage"—Wall Street is placing fresh bullish bets on these names, serving as high-volatility catalysts during the price discovery phase.

Catalyst Calendar

The following catalyst events are sourced from company IR announcements, public earnings calendars, and clinical registries (e.g., ClinicalTrials.gov / company disclosures). They reflect known time windows and are subject to official company announcements. This is not investment advice.

⚠️ Compliance & Disclaimer

This content is compiled by our editorial team based on publicly available institutional research and market data. It does not constitute any investment advice or solicitation to buy or sell securities.

The "Upside" is calculated as (Target Price / Current Price - 1) on a 12-month target basis, which does not equal actual expected returns. Target prices carry risks of lag and deviation.

Liquidity and volatility metrics (such as Volume Ratio, ATR, 52-Week Range) are objective data derived from US market closing prices and are provided strictly for technical reference, not as trading advice.

All rating actions are compiled from public rating information as of Aug 25, and do not represent future rating changes.

Some of the covered stocks are small-caps, which generally exhibit lower liquidity, significant daily volatility, and may still be in loss-making or clinical stages. Their prices are highly sensitive to news flow, and investment risks are significantly higher than for large-cap blue chips. Please exercise extra caution.

Investment involves risks. Decisions should be aligned with your personal risk tolerance, and you should consult a licensed advisor.